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Caremark pharmacy delivery and other pharmacies for
an MS population.
METHODS: Participants in Caremark’s pharmacy claims
database were retrospectively analyzed for compliance on
Glatiramer Acetate therapy. We compared two pharmacy
delivery systems on therapy compliance, episode duration
and cost by delivery episode. Compliance was deﬁned as
the total days supplied over the total calendar days
elapsed. Episodes were deﬁned as continuous time 
periods where prescription and pharmacy delivery system
remained constant. Pharmacy was categorized as Care-
mark (CMX) or Non-Caremark (OTH). Descriptive
information on available MS related medical claim data
was compiled. Compliance and cost differences between
pharmacies were calculated and tested for statistical sig-
niﬁcance using a chi-square test. The study period encom-
passed 08/1998 through 12/2000.
RESULTS: 1516 participants (74.8% female, mean age
44.3 +/- 10.2 years) received Glatiramer Acetate pre-
scriptions from August 1998 through December 2000.
1706 delivery episodes were identiﬁed (CMX 74%, OTH
26%). Compliance to Glatiramer Acetate therapy was
93.2% (se 0.008) for Caremark episodes, and 84.2% (se
0.014) for OTH (p < 0.0001). The duration of drug
therapy regiment was longer (427.1 days, se 8.454) for
CMX episodes Vs OTH (384.6 days, se 16.591, p =
0.0142). Observation of the total health care costs per
participant (N = 39) was $22,523 for CMX, and $81,707
for OTH.
CONCLUSION: Caremark specialty pharmacy services
were associated with higher compliance rates and longer
length of continuous therapy than alternate pharmacy
distribution channels. Though the cost of higher rates of
compliance also increases the pharmacy spend, the total
healthcare costs may be reduced by the maintenance of
increased compliance.
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OBJECTIVES: To assess utilization characteristics of
triptan medications (sumatriptan, naratriptan, zolmitrip-
tan and rizatriptan) and evaluate the need for migraine
quality improvement programs in a managed care 
population.
METHODS: Utilizing a pharmacy claim database from 
a managed care healthplan (over 1.9 million members),
patients who have at least one triptan claim during July
1, 1998–May 31, 2001 were identiﬁed. Patients were
included if continuously enrolled for 12 months follow-
ing the ﬁrst triptan prescription and did not have a triptan
claim during the previous six months. Patients receiving
two or more different triptans within a 3-day period were
considered concurrent triptan users. In order to stan-
dardize the quantity of triptan medication consumed per
patient across the different triptans, “headache equiva-
lents” (HE) were calculated for each medication by divid-
ing the quantity consumed by the maximum quantity
recommended for one headache. The number of patients
exceeding the recommended maximum consumption of 3
HE per month (36 HE per year) was determined.
RESULTS: A total of 5,294 new triptan users were 
identiﬁed. Of these, 39% received only one triptan pre-
scription during the follow-up period, accounting for
11% of the total triptan drug costs. Fifteen percent of the
patients required more than one unique triptan medica-
tion and 4% concurrently used two or more triptans
during the study period. Eight percent exceeded the rec-
ommended maximum consumption of 36 HE per year
and were responsible for 39% of the total triptan 
expenditures.
CONCLUSIONS: A notable number of patients received
only one triptan prescription. A small percentage of
patients received quantities exceeding recommendations
and accounted for a large portion of the triptan pharmacy
costs. Migraine quality improvement programs in these
subsets of patients may be valuable.
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OBJECTIVES: VA (Veteran’s Health Administration)
Cooperative studies convincingly demonstrate that
despite equal efﬁcacy, phenobarbital and phenytoin are
more likely to cause adverse effects, and an expert 
panel recommended carbamazepine as the drug of choice
for adult-onset seizures, with newer medications (lamot-
rigine, gabapentin) being preferable for treating elderly
epileptics. This study examines the state of AED use in
the VA during 1999.
METHODS: We linked administrative (FY1997-FY1999)
and pharmacy databases to identify veterans with
epilepsy who were on anti-epileptic drugs (AEDs, N =
63,853). We used logistic regression to determine if age
(>65 vs. <65) or type of care (primary care or primary
care and neurology) predicted use of: phenobarbital,
phenytoin, carbamazepine, and gabapentin. We con-
trolled for demographics, year diagnosed (1997 or before,
1998, 1999), seizure type (partial, generalized, both), and
number of epilepsy hospitalizations or emergency visits
(severity).
RESULTS: In 1999 patients were on: phenytoin 59%,
phenobarbital 10%, carbamazepine 20%, gabapentin
12%, lamotrigine 2%. Logistic regression indicated that
when year diagnosed, sex, race, and severity were con-
trolled, veterans under 65 were less likely to receive 
phenobarbital (OR .52–.56) and phenytoin (OR .46–
.49), and more likely to receive carbamazepine (OR
